39-41-Wockhardt-Anthem Biosciences-Wyeth India (Now Pfizer India)
15 June 2010 | News
39
Wockhardt
For the past four decades, Wockhardt’s forte has been it’s pharmaceutical and biotechnology business which is backed by top research-oriented technology. The biotechnology unit carved out as a separate strategic unit. Its biotech revenues for the year ended March 31, 2010,clocked at Rs 60 crore. Wockhardt’s pioneering efforts in biotechnology led to the launch of three successful products in the Indian market - Biovac-B (hepatitis B vaccine), Wepox (erythropoietin), and Wosulin (recombinant insulin). The company has also made a breakthrough with Glargine (a novel long-acting insulin). Wockhardt is well prepared to tap the biogenerics opportunity, which is powered by its vision to introduce one biopharmaceutical product every year. This is backed by robust manufacturing, regulatory and marketing infrastructure, offering huge opportunities for outsourcing and potential alliances with biotechnology leaders in the US and Europe.
Its current R&D locations are spread out to Wockhardt – Aurangabad and Mumbai; Negma Laboratories – France; Morton Grove Pharmaceuticals – Illinois, US; and Wockhardt - UK and Pinewood, Ireland.
40
Anthem Biosciences
Anthem Biosciences is a Bangalore based DRAP (Discovery Research Alliance Partner) dedicated to supporting research efforts in the discovery of new compounds by pharmaceutical, biotechnology, specialty chemicals, agriculture chemicals and material science companies. Anthem has achieved a revenue of Rs 32.34 crore for its first full year of operation in 2008-09 and reported an annual turnover of Rs 53 crore in 2008-09. The company hopes to cross the target of Rs 80 crore for the current financial year.
With its best in class infrastructure, Anthem Biosciences can do GMP synthesis from milligram to kilogram and multi-kilogram scale. Apart from modern well equipped labs, the company has a cGMP kilo lab and a versatile GMP pilot plant. Anthem Biosciences is located in an industrial park in Bangalore with a built capacity to house 250 researchers. Currently the company employs over 200 people with plenty of room left for adding extra capacity in labs and people. The overall investments in Anthem have been to the tune of Rs 40 crore.
41
Wyeth India (Now Pfizer India)
Wyeth India is a subsidiary of the US-based pharmaceutical giant, Wyeth and now acquired by Pfizer. It has clocked a a revenue figure of Rs 53 crore (purely from its vaccine business) for the financial year 2009-2010. In the beginning of 2009, its parent company was in news with its acquisition by pharma giant Pfizer for a whopping $68 billion thus blending its biotech portfolio with Pfizer’s pharma product profile. The company has a strong presence in oral contraceptives, folic acid and depilatory cream. It was the first to launch hormone therapy. In the field of vaccines, Wyeth introduced vaccines against HIB and invasive pneumococcal disease in the country. Enbrel, a breakthrough treatment for rheumatoid arthritis; Rapamune, an immuno suppressant for prevention of rejection after renal transplant; Prevenar, a pneumococcal conjugate vaccine; and Tygacil, the world’s first glycilcycline antibiotic, are among internationally known products launched by Wyeth in India. The company has a state-of-the-art manufacturing facility in Verna, Goa.
Wockhardt
| MD | Mr Habil F Khorakiwala |
 |
| Business | Pharmaceutical and Biotechnology business |
|
| Start-up Year | Mid 1960s | |
| Biotech Revenue | Rs 60 crore | |
| Address | Wockhardt Towers, Bandra Kurala Complex, Bandra
(East), Mumbai-400051 |
|
| Tel | +91-22-26596258 | |
| Fax | +91-22-26596801 |
|
| Website | www.wockhardt.in |
For the past four decades, Wockhardt’s forte has been it’s pharmaceutical and biotechnology business which is backed by top research-oriented technology. The biotechnology unit carved out as a separate strategic unit. Its biotech revenues for the year ended March 31, 2010,clocked at Rs 60 crore. Wockhardt’s pioneering efforts in biotechnology led to the launch of three successful products in the Indian market - Biovac-B (hepatitis B vaccine), Wepox (erythropoietin), and Wosulin (recombinant insulin). The company has also made a breakthrough with Glargine (a novel long-acting insulin). Wockhardt is well prepared to tap the biogenerics opportunity, which is powered by its vision to introduce one biopharmaceutical product every year. This is backed by robust manufacturing, regulatory and marketing infrastructure, offering huge opportunities for outsourcing and potential alliances with biotechnology leaders in the US and Europe.
Its current R&D locations are spread out to Wockhardt – Aurangabad and Mumbai; Negma Laboratories – France; Morton Grove Pharmaceuticals – Illinois, US; and Wockhardt - UK and Pinewood, Ireland.
40
Anthem Biosciences
| CEO | Ajay Bharadwaj |
 |
| Business | Contract research services |
|
| Start-up Year | 2006 | |
| Biotech Revenue | Rs 53 crore |
|
| Address | #49, Canara Bank Road, Bommasandra Industrial Area
Phase I, Bommasandra, Hosur Road, Bangalore - 560099 |
|
| Tel | +91-80-40444000 | |
| Fax | +91-80-40444020 | |
| Website | www.anthembio.com |
Anthem Biosciences is a Bangalore based DRAP (Discovery Research Alliance Partner) dedicated to supporting research efforts in the discovery of new compounds by pharmaceutical, biotechnology, specialty chemicals, agriculture chemicals and material science companies. Anthem has achieved a revenue of Rs 32.34 crore for its first full year of operation in 2008-09 and reported an annual turnover of Rs 53 crore in 2008-09. The company hopes to cross the target of Rs 80 crore for the current financial year.
With its best in class infrastructure, Anthem Biosciences can do GMP synthesis from milligram to kilogram and multi-kilogram scale. Apart from modern well equipped labs, the company has a cGMP kilo lab and a versatile GMP pilot plant. Anthem Biosciences is located in an industrial park in Bangalore with a built capacity to house 250 researchers. Currently the company employs over 200 people with plenty of room left for adding extra capacity in labs and people. The overall investments in Anthem have been to the tune of Rs 40 crore.
41
Wyeth India (Now Pfizer India)
| CEO | Kewal Handa |  |
| Business | Biologics, animal healthcare products and
consumer healthcare |
|
| Start-up Year | 2003 | |
| Biotech Revenue | Rs 53 crore |
|
| Address | Level 6 & 7, Platina, Plot No C-59, ‘G’ Block,
Bandra - Kurla Complex, Bandra (E), Mumbai 400 098, India |
|
| Tel | +91-22-26574000 | |
| Fax | - | |
| Website | www.wyethindia.com |
Wyeth India is a subsidiary of the US-based pharmaceutical giant, Wyeth and now acquired by Pfizer. It has clocked a a revenue figure of Rs 53 crore (purely from its vaccine business) for the financial year 2009-2010. In the beginning of 2009, its parent company was in news with its acquisition by pharma giant Pfizer for a whopping $68 billion thus blending its biotech portfolio with Pfizer’s pharma product profile. The company has a strong presence in oral contraceptives, folic acid and depilatory cream. It was the first to launch hormone therapy. In the field of vaccines, Wyeth introduced vaccines against HIB and invasive pneumococcal disease in the country. Enbrel, a breakthrough treatment for rheumatoid arthritis; Rapamune, an immuno suppressant for prevention of rejection after renal transplant; Prevenar, a pneumococcal conjugate vaccine; and Tygacil, the world’s first glycilcycline antibiotic, are among internationally known products launched by Wyeth in India. The company has a state-of-the-art manufacturing facility in Verna, Goa.
